Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis

Journal of Clinical Densitometry

Volumn 16, Issue 2, 2013, Pages 250-256

  McClung, Michael R ^a   Zanchetta, Jose R ^b   Høiseth, Arne ^c   Kendler, David L ^d   Yuen, Chui Kin ^e   Brown, Jacques P ^f   Stonkus, Sigitas ^g   Goemaere, Stefan ^h   Recknor, Chris ⁱ   Woodson, Grattan C ^j   Bolognese, Michael A ^k   Franek, Edward ^l,m   Brandi, Maria Luisa ⁿ   Wang, Andrea ^o   Libanati, Cesar ^o  

^a OREGON OSTEOPOROSIS CENTER   (United States)

^b Instituto de Investigaciones Metabolicas   (Argentina)

^c Curato Røntgeninstitutt   (Norway)

^d Clinical Research Centre   (Canada)

^e Manitoba Clinic   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g KLAIPEDA UNIVERSITY   (Lithuania)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ United Osteoporosis Centers   (United States)

^j Atlanta Research Center   (United States)

^k Bethesda Health Research Center   (United States)

^l CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^m MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

ⁿ UNIVERSITY OF FLORENCE   (Italy)

^o AMGEN INC   (United States)

more..

Author keywords

Bone density; Denosumab; Osteoporosis; Quantitative computed tomography

Indexed keywords

CALCIUM; DENOSUMAB; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SPINE; VITAMIN SUPPLEMENTATION;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84877072861     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2012.02.014     Document Type: Article

References (28)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785-795.
2. Watts N.B., Bilezikian J.P., Camacho P.M., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract 2010, 16:1016-1019.
3. Bousson V., Le Bras A., Roqueplan F., et al. Volumetric quantitative computed tomography of the proximal femur: relationships linking geometric and densitometric variables to bone strength. Role for compact bone. Osteoporos Int 2006, 17:855-864.
4. Eswaran S.K., Gupta A., Adams M.F., Keaveny T.M. Cortical and trabecular load sharing in the human vertebral body. J Bone Miner Res 2006, 21:307-314.
5. Holzer G., von Skrbensky G., Holzer L.A., Pichl W. Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength. J Bone Miner Res 2009, 24:468-474.
6. Keaveny T.M., Hoffmann P.F., Singh M., et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 2008, 23:1974-1982.
7. Khosla S., Melton L.J., Riggs B.L. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. J Bone Miner Res 2011, 26:441-451.
8. Zebaze R.M., Ghasem-Zadeh A., Bohte A., et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010, 375:1729-1736.
9. Genant H.K., Cann C.E., Ettinger B., et al. Quantitative computed tomography for spinal mineral assessment: current status. J Comput Assist Tomogr 1985, 9:602-604.
10. Genant H.K., Engelke K., Fuerst T., et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996, 11:707-730.
11. Black D.M., Bouxsein M.L., Marshall L.M., et al. Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res 2008, 23:1326-1333.
12. Damilakis J., Maris T.G., Karantanas A.H. An update on the assessment of osteoporosis using radiologic techniques. Eur Radiol 2007, 17:1591-1602.
13. Engelke K., Adams J.E., Armbrecht G., et al. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom 2008, 11:123-162.
14. Lacey D.L., Tan H.L., Lu J., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435-448.
15. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
16. Udagawa N., Takahashi N., Yasuda H., et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000, 141:3478-3484.
17. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597-3602.
18. Baron R., Ferrari S., Russell R.G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011, 48:677-692.
19. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059-1066.
20. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008, 93:2149-2157.
21. Brown J.P., Prince R.L., Deal C., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153-161.
22. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
23. Lewiecki E.M., Miller P.D., McClung M.R., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007, 22:1832-1841.
24. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
25. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
26. Genant H.K., Engelke K., Hanley D.A., et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010, 47:131-139.
27. Keaveny T., McClung M., Genant H., et al. Denosumab improves both femoral and vertebral strength in women with osteoporosis: results from the FREEDOM trial. J Bone Miner Res 2010, 25(S1):S31.
28. Boonen S., Adachi J.D., Man Z., et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrin Metab 2011, 96:1727-1736.